Utilization Management
Prior Authorization and Step Therapy Policies for Commercial and Individual Family Business
Complement Inhibitors - Voydeya PA | Policy |
Complement Inhibitors - Zilbrysq PA | Policy |
Complement Inhibitors – Ultomiris Subcutaneous PA Policy | Policy |
Complement System Disorders - WHIM Syndrome - Xolremdi PA | Policy |
Compounded Select Topical Medications PA Policy | Policy |
Contraceptives - Oral, Patch, and Vaginal Ring Products Step Therapy Policy | Policy |
Coronavirus Disease - Evusheld PA | Policy |
Cushing's - Recorlev PA Policy | Policy |
Cushing's - Signifor PA Policy | Policy |
Cushings - Mifepristone PSM | Policy |
Cyclooxygenase - 2 Inhibitor Step Therapy Policy | Policy |
Cystic Fibrosis - Bronchitol PA Policy | Policy |
Cystic Fibrosis - Pulmozyme PA Policy | Policy |
Cystic Fibrosis (Transmembrane Conductance Regulator) - Kalydeco PA | Policy |
Cystic Fibrosis (Transmembrane Conductance Regulator) - Orkambi PA | Policy |
Cystic Fibrosis (Transmembrane Conductance Regulator) - Symdeko PA | Policy |
Cystic Fibrosis (Transmembrane Conductance Regulator) - Trikafta PA | Policy |
Cystic Fibrosis Transmembrane Conductance Regulator - Alyftrek PA | Policy |
Dermatology - Filsuvez PA | Policy |
Dermatology - Gene Therapy - Vyjuvek PA | Policy |
Dermatology - Hyftor PA | Policy |
Desmopressin Products - Nocdurna PA Policy | Policy |
Diabetes - Continuous Glucose Monitoring Systems PA Policy | Policy |
Diabetes - Dipeptidyl Peptidase-4 Inhibitors Care Value Policy | Policy |
Diabetes - Dipeptidyl Peptidase-4 Inhibitors Step Therapy | Policy |
Diabetes - Glucagon-Like Peptide-1 Agonists PA - Optional | Policy |
Diabetes - Glucagon-Like Peptide-1 Agonists PA Policy | Policy |
Diabetes - Metformin Care Value Policy | Policy |
Diabetes - Metformin Step Therapy Policy | Policy |
Diabetes - Mounjaro PA | Policy |
Diabetes - Sodium Glucose Co-Transporter-2 and Dipeptidyl Peptidase-4 Inhibitors Step Therapy | Policy |
Diabetes - Sodium Glucose Co-Transporter-2 Inhibitors Step Therapy | Policy |
Diabetes - Symlin PA Policy | Policy |
Diabetes - Thiazolidinedione Step Therapy Policy | Policy |
Diabetes - Tzield PA | Policy |
Dichlorphenamide PA Policy | Policy |
Dichlorphenamide PSM | Policy |
Diuretics - Loop Products Step Therapy Policy | Policy |
Dronabinol Products PA | Policy |
Dronabinol Products PA with Step Therapy | Policy |
Enspryng PA Policy | Policy |
Enzyme Replacement Therapy - Lamzede PA | Policy |
Enzyme Replacement Therapy - Strensiq PA Policy | Policy |
Enzyme Replacement Therapy - Sucraid PA Policy | Policy |
Epinephrine Auto-Injectors Step Therapy Policy | Policy |
Erectile Dysfunction - Tadalafil (Cialis) PA Policy | Policy |
Erythropoiesis - Stimulating Agents Preferred Specialty Management Policy for High Performance and National Preferred Formularies | Policy |
Erythropoiesis-Stimulating Agents - Epoetin Alfa Products PA Policy | Policy |
Erythropoiesis-Stimulating Agents PSM for High Performance and National Preferred Formularies | Policy |
Estrogen - Transdermal Step Therapy Policy | Policy |
Ezetimibe (Zetia) Step Therapy Policy | Policy |
Fabry Disease - Galafold PA Policy | Policy |
Familial Chylomicronemia Syndrome - Tryngolza PA | Policy |
Fenofibrate Step Therapy Policy | Policy |
Gabapentin Step Therapy Policy | Policy |
Gastroenterology - Eohilia PA | Policy |
Gaucher Disease - Substrate Reduction Therapy Care Value Policy | Policy |
Gaucher Disease - Substrate Reduction Therapy PSM Policy | Policy |
Gaucher Disease Substrate Reduction Therapy - Cerdelga PA Policy | Policy |
Gaucher Disease Substrate Reduction Therapy - Miglustat PA | Policy |
Gonadotropin-Releasing Hormone Agonist - Lupron Depot PA | Policy |
Gonadotropin-Releasing Hormone Agonist - Synarel PA Policy | Policy |
Gonadotropin-Releasing Hormone Agonists - Central Precocious Puberty PA Policy | Policy |
Gonadotropin-Releasing Hormone Agonists - Central Precocious Puberty PA Policy | Policy |
Gonadotropin-Releasing Hormone Agonists - Injectable Long-Acting Products (Lupron Depot-Ped and Triptodur) PA | Policy |
Gonadotropin-Releasing Hormone Antagonists - Oriahnn PA Policy | Policy |
Gonadotropin-Releasing Hormone Antagonists - Orilissa PA Policy | Policy |
Gout Medications Step Therapy Policy | Policy |
Growth Disorders - Growth Hormone Long-Acting Products PSM | Policy |
Growth Disorders - Growth Hormone PA | Policy |
Growth Disorders - Growth Hormone Short-Acting Products PSM Policy | Policy |
Growth Disorders - Increlex PA Policy | Policy |
Growth Disorders - Ngenla PA | Policy |
Growth Disorders - Sogroya PA | Policy |
Growth Disorders - Voxzogo PA | Policy |
Hemangeol PA with Step Therapy Policy | Policy |
Hematology - Adzynma PA | Policy |
Hematology - Cablivi PA Policy | Policy |
Hematology - Gene Therapy - Casgevy PA | Policy |
Hematology - Gene Therapy - Lyfgenia PA | Policy |
Hematology - Gene Therapy - Zynteglo PA | Policy |
Hematology - Pyrukynd PA | Policy |
Hemophilia - Alhemo PA | Policy |
Hemophilia - Altuviiio PA | Policy |
Hemophilia - Gene Therapy - Beqvez PA | Policy |
Hemophilia - Gene Therapy - Hemgenix PA | Policy |
Hemophilia - Hympavzi PA | Policy |
Hemophilia - Recombinant Factor IX Products | Policy |
Hepatitis C - Epclusa PA Policy | Policy |
Hepatitis C - Harvoni PA Policy | Policy |
Hepatitis C - Ribavirin PA Policy | Policy |
Hepatitis C - Viekira Pak PA Policy | Policy |
Hepatitis C - Vosevi PA Policy | Policy |
Hepatitis C - Zepatier PA Policy | Policy |
Hepatitis C Virus (HCV) Direct Acting Antivirals (DAAs) PSM for National Preferred Formulary and Basic Formulary | Policy |
Hepatitis C Virus Direct - Acting Antivirals PSM Policy for National Preferred Formulary and Basic Formulary | Policy |
Hepatology - Iqirvo PA | Policy |
Hepatology - Livdelzi PA | Policy |
Hepatology - Ocaliva PA Policy | Policy |
Hepatology - Rezdiffra PA | Policy |